	FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					INT'L FILING NO. INT'L FILING DATE APPLICANT			
					GROUP			1624	
					EXAMINER			Coleman	
					ATTORNEY DOCKET NO			. PB60780USw	
			U.S. I	PATENT DO	OCUMENTS				
Examiner Initials		Patent Number	Issue Date	Name		Class	Subclass	Filing Date If Appropriate	
/B.C./	1.	4,210,749	7/1/1980	Shetty		542	469		
/B.C./	2.	5,364,791	11/15/1994	Vegeto et	<u></u> a1	435	320.1		
/B.C./	3.	5,874,534	2/23/1999	Vegeto et al.		530	350		
/B.C./									
/5.0./	4.	5,935,934	8/10/1999	Vegeto et	aı	514	44		
			FOREIG	I ON PATENT	T DOCUMENT	<u> </u>			
		Document	Publication					Translation	
		Number	Date	0	Country	Class	Subclass	Yes   No	
** /B.C./	5.	WO96/05194	2/22/1996	PCT	•			abstract only	
/B.C./	6.	WO00/21951	4/20/2000	PCT				1	
** /B.C./	7.	WO00/23437	4/27/2000	PCT				abstract only	
/B.C./	8.	WO01/03680	1/18/2001	PCT		1			
, <b>*</b> /B.C./	9.	WO01/87834	11/22/2001	PCT				abstract only	
** /B.C./	10.	WO02/02530	1/10/2002	PCT		+		abstract only	
* /B.C./	11.	WO02/02530 WO02/14513	2/21/2002	PCT				abstract only	
20.3								<u> </u>	
* /B.C./ * /B.C./	12.	WO02/15934	2/28/2002	PCT				abstract only	
	13.	WO02/46186	6/13/2002	PCT				abstract only	
/B.C./	14.	WO02/040471	5/23/2002	PCT					
/B.C./	15.	WO02/059115	8/1/2002	PCT					
/B.C./	16.	WO03/068752	8/21/2003	PCT					
/B.C./	17.	WO04/018432	3/4/2004	PCT					
/B.C./	18.	WO04/056369	7/8/2004	PCT					
/B.C./	19.	1268243	3/22/1972	GB					
**7B.C./	20.	2207430	8/23/1973	DE				no	
7B.C./	21.	0612741	8/31/1994	EP					
** /B.C./	22.	2171879	9/28/1973	FR				no	
** /B.C./	23.	2001226269	8/21/2001	JР				no	
	20.	OTHER DOCUM			Title Iournal	Data Paga Nun	hor Etc.)	1 10	
/B.C./	24.	FUKUIJ et al., M	olecular Cloning		· · · · · · · · · · · · · · · · · · ·			l Biophy Res.	
/B.C./	Comm., <b>201(2)</b> :894-901 (1994).  25. AUSTIN et al., Novel 2,3,4,5-Tetrahydro-1 <i>H</i> -3-benzazepines with High Affinity							vity for the	
/D.U./		Dopamine D <sub>3</sub> Receptor, Bioorg. & Med. Chem Ltrs. 10:2553-2555 (2000).							
/B.C./	26.	SMIT et al., Regulation of the human histamine H1 receptor stably expressed in Chinese hamster ovary cells, Br. J. Pharmacol. 117(6):1071-1080 (1996).							
/B.C./	27.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonist and antagonists on cognitive performance and							
, , ,	20	scopolamine-induced amnesia," Behavioral Brain Res. 104:147-155 (1999).							
/B.C./	28. LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," TiPS 19:177-1							<b>2S 19</b> :177-183	
	29.	(May 1998).  LOVENBERG et al., "Cloning and Functional Expression of the Human Histamine H <sub>3</sub> Receptor," Molecular							
/B.C./		Pharmacology 55:1101-1107 (1999).							
/B.C./	30.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).							
/B.C./	31.	SARLO and RENZI, 2-Methylisoxazolin-5-Ones-II, Tetrahedron 22:2995-2999 (1966).							
/B.C./	32.	SCHLICKER et al., Modulcation of Neurotransmitter Release via histamine H <sub>3</sub> heteroreceptors, Fund. Clin. Pharmacol. <b>8</b> :128-137 (1994).							
EXAMINER		/Brenda Coler				DATE	CONSIDERE 09/02/2008	D	
EXAMMED	· Indti-	al if citation conside	ared whather co	not citation	s in conformance				
		at it citation consident of ormance and not of							